INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
npj Vaccines
October 2021
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
| Title | Disease Target | Product |
|---|---|---|
| Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019 |
Zika | INO-A002 |
| In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019 |
Zika | INO-A002 |
| In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018 |
Ebola | |
| Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018 |
CTLA-4 | |
| Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017 |
Prostate Cancer | |
| DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017 |
Influenza |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2022 INOVIO Pharmaceuticals. All rights reserved.
